Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

November 2, 2018November 2, 2018

Antibiotic Use May Promote IBD Development by Disrupting Gut Immune Cells, Mouse Study Suggests

News

Antibiotics can disrupt immune cells residing in the gut, triggering the rise of pro-inflammatory cells and reducing healthy bacteria — two steps key in the development of inflammatory bowel disease ... Read more

September 5, 2018September 5, 2018

Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial

News

Abivax‘s small, anti-inflammatory molecule ABX464 significantly increased clinical remission and mucosal healing over placebo in patients with moderate to severe active ulcerative colitis resistant to other therapies, top-line results from a ... Read more

August 24, 2018August 24, 2018

Eating Strawberries Reduces Colon Inflammation, Improves Gut Health in IBD Mouse Model

News

Less than a cupful of whole strawberries a day led to a significant decrease in colon inflammation and reversal of the pro-inflammatory gut microbiome in a mouse model of inflammatory ... Read more

August 3, 2018August 3, 2018

Pfizer’s Xeljanz Approved in EU for Adults with Moderate to Severe Ulcerative Colitis

News, Ulcerative colitis

The European Commission has approved Pfizer‘s Xeljanz (tofacitinib) for the treatment of adults with moderate to severe active ulcerative colitis (UC) who have failed to fully respond to other therapies. The ... Read more

July 18, 2018July 18, 2018

Phase 1 Trial of Investigational BT-11 Begins Dosing First Volunteers, Landos Announces

News

A Phase 1 clinical trial testing Landos Biopharma’s investigational therapy BT-11 for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), has begun dosing healthy volunteers. Landos plans to ... Read more

June 27, 2018June 27, 2018

Aerpio Licenses Development, Sales Rights of IBD Candidate AKB-4924 to Gossamer Bio

News

Aerpio Pharmaceuticals announced a licensing agreement with Gossamer Bio to develop and commercialize Aerpio’s investigative therapy AKB-4924 as a treatment for inflammatory bowel disease (IBD). AKB-4924 (to be changed to GB004) is a hypoxia-inducible factor-1 alpha ... Read more

June 22, 2018June 22, 2018

Opioid Use May Contribute to Imbalances in the Gut and Spur Inflammation, Studies Find

News

Extended use of opioids promotes imbalances in the gut microbiome and triggers changes that worsen inflammation in the intestine, according to results of studies in a mouse model of colitis ... Read more

June 15, 2018June 15, 2018

Protein Complex May Offer Way of Limiting Inflammatory Reactions, Study Suggests

News

New research unveils how two molecules, protein complexes called S100A8 and S100A9, are regulated in order to limit an inflammatory responses to sites where they are needed, preventing the spread ... Read more

June 1, 2018June 1, 2018

FDA Approves Pfizer’s Xeljanz, an Oral Twice Daily Treatment for Adults with Moderate to Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved the oral therapy Xeljanz (tofacitinib), by Pfizer, to treat adults with moderately to severely active ulcerative colitis (UC), the company announced. The treatment regimen calls ... Read more

May 21, 2018May 21, 2018

Immuron’s IMM-124E Significantly Eases Symptoms of Chronic Colitis in Mouse Model, Company Reports

News

Immuron’s investigational therapy IMM-124E significantly reduced intestinal inflammation in mice models of chronic colitis, the company reports. These results add to previous preclinical evidence showing the therapy to also of benefit ... Read more